2008 ASCO Genitourinary Cancers Symposium: Updates in the Management of Prostate and Kidney Cancers - CME
C. Dean Buckner, MD

ASCO 2007: Targeted Therapy and Renal Cell Carcinoma: Are We Making Progress?
Robert J. Amato, DO, Weill Medical College of Cornell University, University of Texas Health Science Center - Houston, The Methodist Hospital Research Institute, Houston, Texas

ASCO 2007: Update on the Management of Genitourinary Malignancies
Nancy A. Dawson, MD – Lombardi Comprehensive Cancer Center

Current Topics

Sutent® Provides Superior Quality of Life Compared with Interferon in Kidney Cancer (8/14/2008)
The targeted agent Sutent® (sunitinib) provides superior quality of life compared with interferon alfa for patients with advanced renal cell carcinoma (RCC). These results were recently published in the August 1, 208 issue of Journal of Clinical Oncology.

Adjuvant Chemotherapy Does Not Adversely Affect Quality of Life of Elderly Patients with Colorectal Cancer (8/11/2008)
Researchers from France have reported that patients 75 years of age or older with Stage III colon or rectal cancer receiving adjuvant chemotherapy or radiotherapy did not have negative effects on quality-of-life parameters compared with patients not receiving adjuvant therapy. The details of this study appeared in the August 15, 2008 issue of Cancer.

Everolimus Improves Progression-free Survival in Renal Cell Cancer (8/1/2008)
Researchers affiliated with an international randomized Phase III trial have reported that everolimus (RAD001) significantly prolongs progression-free survival among patients with advanced renal cell cancer (RCC) who have progressed following prior therapies. These results were published in an early online publication in The Lancet on July 23, 2008.

Risk Factors for Sutent® Toxicity in Renal Cell Cancer Defined (7/23/2008)
Researchers from the Netherlands have reported that severe toxicity following treatment of advanced renal cell carcinoma (RCC) with Sutent® (sunitinib) is related to low body surface, high age, and female gender. The details of this study appeared in the July 15, 2008 issue of the British Journal of Cancer.

Thalomid® and Revlimid® Active as Primary Treatment for Metastatic Renal Cell Carcinoma (7/1/2008)
Researchers from Methodist Hospital in Houston, Texas, have reported that both Revlimid® (lenalidomide) and Thalomid® (thalidomide) have significant activity in newly diagnosed patients with metastatic renal cell carcinoma (MRCC). The details of these two studies were published in the June 2008 issue of the American Journal of Clinical Oncology.